All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is happy to present a Visual Abstract representing key data from the phase III AGILE study, evaluating ivosidenib + azacitidine vs placebo + azacitidine in patients with previously untreated IDH1-mutant acute myeloid leukemia (AML).
Visual Abstract Download!
Click here to download this visual abstractClick To Download
ASH 2022 roundup: IDH inhibitors
Here, we summarize safety and efficacy data for enasidenib and ivosidenib and the association between IDH mutations in patients with AML and relapse rates after allo-HSCT is discussed.
The latest on venetoclax combinations in AML from ASH 2021
The BCL-2 inhibitor, venetoclax, has transformed the treatment landscape for acute myeloid leukemia (AML), particularly in cases where patients are considered ineligible for intensive...
Subscribe to get the best content related to AML delivered to your inbox